| Korean J Clin Microbiol. 2009 Sep;12(3):122-128. Korean. Published online September 30, 2009. https://doi.org/10.5145/KJCM.2009.12.3.122 | |
| Copyright © 2009 The Korean Society of Clinical Microbiology | |
Da-Woon Kim,
Jong Hee Shin,
Seung Jung Kee,
Soo-Hyun Kim,
Myung Geun Shin,
Soon Pal Suh
and Dong Wook Ryang
| |
| Department of Laboratory Medicine, Chonnam National University Medical School, Gwangju, Korea. | |
| Correspondence: Jong Hee Shin, Department of Laboratory Medicine, Chonnam National University Medical School, 671, Jebong-ro, Dong-gu, Gwangju 501-757, Korea. (Tel) 82-62-220-5342, (Fax) 82-62-224-2518,
| |
| Received April 20, 2009; Revised June 05, 2009; Accepted July 15, 2009. | |
 This article has been cited by 3 articles in   This article has been cited by 2 articles in KoMCI. This article has been cited by Google Scholar. | |
|
Abstract
| |
|
Background
VITEK-2 yeast susceptibility test (AST-YS01; bioMerieux, Hazelwood, MO, USA) has recently been introduced as a fully automated commercial antifungal susceptibility test system that determines MIC (minimum inhibitory concentrations) endpoints spectrophotometrically, thereby eliminating subjective errors. We compared the VITEK-2 system with the CLSI (the Clinical and Laboratory Standards Institute) M27 method for susceptibility testing of Candida isolates from Korea.
Methods
A total of 175 Candida bloodstream isolates were collected from two hospitals during a 18-month period. We compared the MIC results for amphotericin B, fluconazole and voriconazole obtained with the VITEK-2 system to those obtained by the CLSI M27 broth microdilution method after 24-hr and 48-hr incubation.
Results
VITEK-2 system MIC endpoints for 175 isolates were determined after 11.75 to 35.50 hr of incubation (mean, 16.3±4.8 hr). The essential agreement (within 2 dilutions) between amphotericin B, fluconazole and voriconazole MICs obtained by the VITEK-2 system and CLSI method was 98.3%, 90.9% and 96.0%, respectively, at 24-hr incubation and 100%, 92.6% and 94.9%, at 48-hr incubation. The categorical discrepancy for fluconazole was 6.3% (major error, 2.9% and minor error, 3.4%) at 24-hr and 6.3% (major error, 2.3% and minor error, 4.0%) at 48-hr. The categorical discrepancy for voriconazole was 1.7% (major error, 1.1% and minor error, 0.6%) at both 24-hr and 48-hr. There were no very major errors for fluconazole and voriconazole.
Conclusion
The VITEK-2 antifungal susceptibility test system appears to be rapid and highly correlative with the CLSI method, sugesting that this system can be effective for antifungal susceptibility testing for Candida species in the clinical laboratory. |
|
Keywords: Candida; VITEK-2; Antifungal susceptibility; CLSI |
|
|
Tables
|
|
|
|
|
References
|
| 1. | Shin JH. Antifungal drug susceptibility. Hanyang Med Rev 2006;26:79–85.
|
| 2. | Clinicaland Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard, Third ed., M27-A3. Wayne, PA: Clinical and Laboratory Standards Institute; 2008. |
| 3. | Murray PR, Baron EJ, et al., editors. Manual of Clinical Microbiology. 9th ed. Washington DC: American Society for Microbiology; 2007. pp. 1972-1986. |
| 4. | Pfaller MA, Yu WL. Antifungal susceptibility testing. New technology and clinical applications. Infect Dis Clin North Am 2001;15:1227–1261. 
|
| 5. | Pfaller MA. Antifungal susceptibility testing methods. Current Drug Targets 2005;6:929–943.
|
| 6. | Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 2007;45:796–802.
|
| 7. | Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG. Multicenter comparison of the VITEK2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp. J Clin Microbiol 2007;45:3522–3528.
|
| 8. | Lee JS, Shin JH, Lee K, Kim MN, Shin BM, Uh Y, et al. Species distribution and susceptibility to azole antifungals of Candida bloodstream isolates from eight university hospitals in Korea. Yonsei Med J 2007;48:779–786. 
|
| 9. | Pfaller MA, Diekema DJ, Rex JH, Espinel-Ingroff A, Johnson EM, Andes D, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006;44:819–826.
|
| 10. | Park JY, Shin JH, Uh Y, Kim EC, Kee SJ, Kim SH, et al. In vitro amphotericin B susceptibility of Korean bloodstream yeast isolates assessed by the CLSI broth microdilution method, Etest, and minimum fungicidal concentration test. Korean J Lab Med 2008;28:346–352.
|
| 11. | Antoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JP, et al. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine (Baltimore) 2003;82:309–321.
|
| 12. | Food and Drug Administration. Class II special controls guidance document: antimicrobial susceptibility test (AST) systems; guidance for industry and FDA. Rockville, MD: Food and Drug Administration; 2007. |
| 13. | Kim SH, Shin JH, Kim EC, Lee K, Kim MN, Lee WG, et al. The relationship between antifungal usage and antifungal susceptibility in clinical isolates of Candida: a multicenter Korean study. Med Mycol 2009;47:296–304.
|
Evaluation of VITEK-2 Antifungal Susceptibility Test (AST-YS01) for Candida Species Isolates in Korea
